For research use only. Not for therapeutic Use.
MYC-RIBOTAC(CAT: I040996) is a ribonuclease-targeting chimera (RIBOTAC) designed to selectively degrade MYC mRNA, offering a novel approach to targeting MYC-driven cancers. By harnessing the cellular RNA degradation machinery, MYC-RIBOTAC promotes the selective cleavage of MYC transcripts, leading to reduced oncoprotein expression and inhibition of tumor growth. This compound is a valuable tool for cancer research, particularly in studying transcriptional regulation, RNA-targeted therapies, and MYC-dependent oncogenic pathways. Suitable for biochemical, cellular, and preclinical studies, MYC-RIBOTAC provides a promising strategy for RNA-based drug discovery. For research use only; not for human or clinical applications.
| Synonyms | ethyl (5Z)-5-[[4-[2-[2-[2-[2-[[3,5-bis[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]carbamoylamino]benzoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]-3-hydroxyphenyl]methylidene]-4-hydroxy-2-phenyliminothiophene-3-carboxylate |
| Molecular Formula | C55H58N10O11S |
| Purity | ≥95% |
| IUPAC Name | ethyl (5Z)-5-[[4-[2-[2-[2-[2-[[3,5-bis[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]carbamoylamino]benzoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]-3-hydroxyphenyl]methylidene]-4-hydroxy-2-phenyliminothiophene-3-carboxylate |
| InChI | InChI=1S/C55H58N10O11S/c1-2-75-53(69)47-48(67)46(77-52(47)61-39-6-4-3-5-7-39)31-35-8-17-45(44(66)30-35)76-29-28-74-27-26-73-25-24-72-23-22-60-51(68)38-32-42(64-54(70)62-40-13-9-36(10-14-40)49-56-18-19-57-49)34-43(33-38)65-55(71)63-41-15-11-37(12-16-41)50-58-20-21-59-50/h3-17,30-34,66-67H,2,18-29H2,1H3,(H,56,57)(H,58,59)(H,60,68)(H2,62,64,70)(H2,63,65,71)/b46-31-,61-52? |
| InChIKey | WLPGURIVBVLQPT-AWPFAIGZSA-N |
| SMILES | CCOC(=O)C1=C(C(=CC2=CC(=C(C=C2)OCCOCCOCCOCCNC(=O)C3=CC(=CC(=C3)NC(=O)NC4=CC=C(C=C4)C5=NCCN5)NC(=O)NC6=CC=C(C=C6)C7=NCCN7)O)SC1=NC8=CC=CC=C8)O |
